Will Bupa Arabia, Tawuniya, MedGulf, and AXA Cooperative cover this?

Each insurer assesses named-patient imports case by case. Some reimburse fully when Blincyto is on their formulary even if not currently stocked, some reimburse a percentage subject to copay, and many require pre-authorisation. We supply the documentation set that allows your insurer to assess the case; the claim itself sits with you or your hospital.

Is the FDA-approved indication recognised by SFDA?

The SFDA named-patient pathway exists precisely to permit access when the local registration or stocking lags the FDA label. The application documents the FDA indication, the reference-authority approval, and the local gap; SFDA review focuses on the clinical justification rather than re-litigating the FDA decision.

My physician is licensed in one emirate / state / province and the hospital is in another. Is that fine?

Any Saudi-licensed physician practicing in good standing in the jurisdiction of the dispensing facility has signing authority on the clinical justification letter. The Saudi Commission for Health Specialties (SCFHS) and the SFDA verifies the active license; the SFDA application records both the prescribing physician and the dispensing facility.

Can I receive Blincyto at home?

The dispensing facility must be Saudi-licensed. The hospital outpatient or specialty pharmacy releases the medicine to you after final verification, and you then administer or self-administer at home where the FDA label permits, after the dispensing pharmacy's training. The cold-chain or controlled-storage handoff ends at the dispensing pharmacy; home storage and any handling protocol are part of your patient onboarding kit.

What about competitors or alternative therapies in the same class?

Choice of therapy depends on the patient's full phenotype, prior therapy, and the prescriber's judgment. Reserve Meds coordinates whichever medicine the physician has prescribed; we do not substitute, advise on substitution, or promote one brand over another.

Indicative quote provided at intake. Delivered quote within 24h.Get my quote

Blincyto access in Saudi Arabia: the SFDA named-patient pathway

How patients in the Kingdom of Saudi Arabia legally obtain Blincyto (blinatumomab) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.

Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.

Quick orientation

Patients in Saudi Arabia access Blincyto (blinatumomab) for B-cell precursor acute lymphoblastic leukaemia in adult and pediatric patients with minimal residual disease or in the relapsed/refractory setting under the FDA label through the SFDA named-patient pathway, a Saudi Food and Drug Authority-administered mechanism that allows a Saudi-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and real cost in SAR.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

Reserved for you.

How Blincyto reaches patients in Saudi Arabia

Blincyto (blinatumomab, bispecific T-cell engager targeting CD19, FDA-approved 2014 with expanded label for B-cell precursor acute lymphoblastic leukaemia in adult and paediatric patients in the relapsed/refractory and minimal-residual-disease-positive settings; FDA-approved June 2024 for consolidation in CD19-positive Philadelphia-chromosome-negative B-cell precursor ALL across treatment phases) is registered with the SFDA through Amgen's local affiliate for selected indications; check current status at sfda.gov.sa/en/drugs-list. Where the prescribed indication, dose, or formulation is not locally stocked, Saudi patients access Blincyto via the SFDA Special Access Programme for unregistered drugs (Pathway B for hospital-led emergency or compassionate use) or via Personal Importation under SFDA Document Drug-6567E for patient-led applications. The Blincyto-specific clinical justification must document: CD19-positive B-cell precursor ALL (cytometry confirmation), Philadelphia-chromosome status, MRD status by flow cytometry or next-generation sequencing where indication-relevant, prior treatment lines, and the FDA-label dosing schedule (continuous IV infusion via 7-day CADD pump). Critical safety: cytokine release syndrome and neurotoxicity monitoring per the FDA Boxed Warning; the prescribing haematology and oncology team's inpatient or close-outpatient surveillance plan is documented in the application. The supporting medical report must be dated within 6 months of submission. SFDA processing is same-day to several-working-day.

Where Blincyto is administered in Saudi Arabia

Blincyto is administered as continuous IV infusion via portable CADD pump in haematology and BMT settings with cytokine release syndrome and neurotoxicity surveillance capacity. Saudi tertiary haematology and BMT centres include King Faisal Specialist Hospital and Research Centre (KFSHRC) Department of Adult Haematology and Stem Cell Transplant in Riyadh and Jeddah at kfshrc.edu.sa, the country's largest BMT and cellular-therapy programme; King Fahad Medical City (KFMC) Haematology in Riyadh at kfmc.med.sa; King Abdulaziz Medical City (KAMC) Haematology and BMT in Riyadh and Jeddah, with the Princess Noorah Oncology Center BMT unit; Prince Sultan Military Medical City Haematology in Riyadh; King Abdullah Specialist Children's Hospital Paediatric Haematology and BMT in Riyadh for paediatric Blincyto candidates; and King Fahad Specialist Hospital Dammam Haematology and BMT in the Eastern Province. KFSHRC and KAMC publish departmental chairs and run the country's largest CD19-positive ALL clinical case load; both hold institutional importation licences under the SFDA Special Access Programme and routinely use Blincyto in the FDA-label pathways. Paediatric ALL cases concentrate at King Abdullah Specialist Children's Hospital and KFSHRC paediatric.

What Blincyto costs in Saudi Arabia

The US reference WAC for Blincyto is approximately USD 89,000 per 28-day cycle at the standard adult dose (9 mcg per day for 7 days then 28 mcg per day continuous) per Amgen disclosures and Drugs@FDA at accessdata.fda.gov/scripts/cder/daf. Total course cost for 2 induction cycles plus consolidation cycles can run USD 200,000 to USD 400,000 depending on regimen. Amgen Saudi Arabia distributes Blincyto for the SFDA-registered indications; local SAR pricing for the registered presentations is available through NUPCO procurement at nupco.com for institutional purchasing but is not consistently published as a public list price for retail-pharmacy access. The SAR is pegged to the USD at approximately 3.75 SAR per USD; the peg removes FX volatility from the price calculation. Price snapshot: 2026-05-31. Cost layers: cold-chain international logistics into Saudi Arabia where the named-patient-import lane is invoked (mid four-figure USD for refrigerated lanes), SFDA clearance fees (nominal), the CADD pump and 7-day continuous-infusion administration costs at the dispensing hospital (non-trivial), and Reserve Meds concierge fee itemised separately. For Saudi nationals at KFSHRC, KFMC, or KAMC the drug is typically borne by NUPCO institutional procurement.

Funding and access barriers for Blincyto in Saudi Arabia

B-cell precursor ALL is a well-recognised adult and paediatric haematologic malignancy in Saudi tertiary practice; KFSHRC, KFMC, KAMC, and King Abdullah Specialist Children's Hospital run high-volume ALL case loads. Public funding: Saudi nationals receive specialty oncology and haematologic-malignancy care at no direct cost at MOH-affiliated specialty centres; NUPCO at nupco.com is the single-window procurement entity and Blincyto for the SFDA-registered indications is on the NUPCO procurement list. For FDA-label indications not yet SFDA-registered (the named-patient import lane), the institutional Special Access Programme is the route, with the clinical committee at the treating institution approving on documented criteria. The Council of Health Insurance Essential Benefits Package adjudicates the floor for cooperative-insurance coverage; major Saudi insurers (Bupa Arabia, Tawuniya, MedGulf, AXA Cooperative, Al Rajhi Takaful, Walaa Cooperative, SAICO) extend Blincyto coverage with higher-tier policies under prior authorisation. KSrelief funds case-by-case treatment for non-citizens under humanitarian programmes. The 7-day continuous-infusion CADD pump administration is logistically demanding; the institutional setting requirement (haematology-experienced unit) is a meaningful operational gate but is not a regulatory barrier per se.

Recent regulatory and access news for Blincyto

FDA approved (June 2024) Blincyto for consolidation in CD19-positive Philadelphia-chromosome-negative B-cell precursor ALL across treatment phases including newly diagnosed (Eastern Cooperative Oncology Group ECOG-ACRIN E1910 trial); the approval significantly broadens the eligible population to include newly diagnosed patients in consolidation. The FDA approval letter is at accessdata.fda.gov/scripts/cder/daf. EMA confirmed mirror indications across the original and expanded labels; the EPAR is at ema.europa.eu/medicines/Blincyto. The SFDA News feed at sfda.gov.sa/en/news documents periodic SFDA registration-approval announcements; Amgen Saudi Arabia has progressed Blincyto label expansions through SFDA submissions on a phased basis. No SFDA bulletin specific to Blincyto over the last 12 months as of 2026-05-31.

Where Reserve Meds fits in Blincyto cases

Reserve Meds is a US-based concierge coordinator. We do not replace your treating physician, we do not replace SFDA, and we do not replace your dispensing pharmacy. For Blincyto specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into Saudi Arabia, and assign a single named coordinator through the case. Standard named-patient coordination under our specialty playbook applies. Presentation selection, dose-band confirmation, and patient onboarding for self-administration where applicable are the recurring operational fundamentals we expect for this drug.

Operationally, a typical Blincyto case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the SFDA application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the named coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.

Saudi BMT programmes at KFSH&RC handle BiTE continuous-infusion administration with structured CRS and neurotoxicity monitoring per the FDA REMS.

Next step

If your Saudi physician has prescribed Blincyto and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.

Start your Blincyto case Or message us on WhatsApp